Eagle Pharmaceuticals, Inc. (EGRX)
$
1.03
+0.18 (17.48%)
Key metrics
Financial statements
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Eagle Pharmaceuticals, Inc. is a pharmaceutical company focusing on the development and commercialization of product candidates aimed at treating diseases related to the central nervous system, metabolic critical care, and oncology primarily within the United States. The total costs and expenses for the company are $235,650,000.00 reflecting its overall spending. The company provides several therapeutic options including Ryanodex for malignant hyperthermia, and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Additionally, its product candidates encompass EP-4104, designed for organophosphate exposure treatment, PEMFEXY, a ready-to-use/dilute liquid formulation of pemetrexed intended for non-small cell lung cancer and mesothelioma, EA-114 (fulvestrant) for HR+/HER- breast cancer, and Vasopressin injection, which is used to enhance blood pressure in adults experiencing vasodilatory shock. The company has also established license and collaboration agreements with Combioxin, SA for the rights to develop and commercialize CAL02, an antitoxin agent targeting severe pneumonia when used alongside traditional antibacterial treatments. Moreover, it has partnered with AOP Orphan Pharmaceuticals GmbH for the commercial rights to Landiolol, a novel therapeutic aimed at the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. Alongside these partnerships, Eagle Pharmaceuticals has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat HR+/HER2- breast cancer and high-risk metastatic sarcomas. The company reported an income before tax of $61,433,000.00 showcasing its pre-tax profitability, while the income before tax ratio is 0.19 reflecting the pre-tax margin. Furthermore, the company incurred an interest expense of $4,045,000.00 indicating its debt servicing obligations, and the earnings per share (EPS) is reported at $2.76 which points to the company’s profitability on a per-share basis. In addition to its robust pharmaceutical offerings, the stock is affordable at $0.88 making it suitable for budget-conscious investors. With a market capitalization of $13,346,946.00 the company is classified as a small-cap player, reflecting its position within the broader market. The stock has a low average trading volume of 12,227.00 which indicates lower market activity relative to larger market participants. Eagle Pharmaceuticals is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth. These factors collectively position the company for continued impact in the pharmaceutical domain while attracting interest from diverse investors seeking potential opportunities within the market.
What is Eagle Pharmaceuticals, Inc. (EGRX)'s stock forecast?
Analysts predict Eagle Pharmaceuticals, Inc. stock to fluctuate between $0.00 (low) and $6.37 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Eagle Pharmaceuticals, Inc.'s market capitalization?
As of 2025-04-02, Eagle Pharmaceuticals, Inc.'s market cap is $13,346,946, based on 12,958,200 outstanding shares.
How does Eagle Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Eagle Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Eagle Pharmaceuticals, Inc. (EGRX) stock?
To buy Eagle Pharmaceuticals, Inc. (EGRX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for EGRX. Place an order (Market, Limit, etc.).
What is the best time to invest in Eagle Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Eagle Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $316,610,000 | EPS: $2.76 | Growth: -518.18%.
Where can I find Eagle Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.eagleus.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Eagle Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Eagle Pharmaceuticals, Inc. stock?
All-time high: $58.25 (2021-10-04) | All-time low: $0.00 (2024-10-28).
What are the key trends affecting Eagle Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
12 days ago
WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has approved an amendment to its previously disclosed limited duration stockholder rights plan (the “Rights Plan”) to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in full force and effect in accordance with its terms.
globenewswire.com
5 months ago
WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has notified The Nasdaq Stock Market, LLC (“Nasdaq”) of its intent to file its own Form 25 (Notification of Removal of Listing) with the U.S. Securities and Exchange Commission (the “SEC”) to complete the previously-disclosed process to delist the Company's common stock, par value $0.001 per share (the “Common Stock”), from the Nasdaq Global Market in advance of Nasdaq's anticipated filing of a Form 25 with the SEC.
accesswire.com
5 months ago
WILMINGTON, DE / ACCESSWIRE / October 22, 2024 / Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ GM:EGRX) on behalf of stockholders.
gurufocus.com
6 months ago
On October 3, 2024, Union Square Park Capital Management, LLC (Trades, Portfolio) made a significant move in the pharmaceutical sector by acquiring 1,191,490 shares of Eagle Pharmaceuticals Inc (EGRX, Financial). This transaction marked a new holding for the firm, purchased at a price of $1.99 per share.
globenewswire.com
7 months ago
WOODCLIFF LAKE, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on August 21, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that pursuant to Nasdaq Listing Rule 5810(d)(2), the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) serves as an additional and separate basis for delisting.
globenewswire.com
10 months ago
WOODCLIFF LAKE, N.J., May 22, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on May 20, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it has initiated a process to delist the Company's securities from Nasdaq because the Company had not filed its Form 10-Q for the quarter ended September 30, 2023 (the “Q3 2023 Form 10-Q”) and its Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”) by May 13, 2024. The Notice further advises the Company that, pursuant to Nasdaq Listing Rule 5810(d)(2), the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Q1 2024 Form 10-Q”) serves as an additional and separate basis for delisting.
globenewswire.com
a year ago
-- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring PONV rescue versus placebo -- -- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring PONV rescue versus placebo --
globenewswire.com
a year ago
WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on April 8, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”), with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic reports with the SEC.
accesswire.com
a year ago
NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66577&wire=1 or contact Joseph E. Levi, Esq.
prnewswire.com
a year ago
If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/EGRX.
See all news
